MEDIVIR - Simeprevir- Good with and without IFN Combinations!
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1, 2, STELARA, GSK-1605786, Vercirnon, Traficet-EN, Japanese Pharma, Takeda, 4502
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1, 2, STELARA, GSK-1605786, Vercirnon, Traficet-EN, Japanese Pharma, Takeda, 4502
Approval of Simeprevir/IFN/RBV combination (TMC435, once daily Protease Inhibitor, PI, R, HCV, partnered with Tibotec/JNJ) in Japan and progress in IFN free combinations with various drugs has helped Medivir’s (MVIR) stock to reach 52 weeks high after a long wait. With a priority status in US, approval of Simeprevir/IFN/RBV in GT1 pts should happen on or before Nov. 28th 2013 followed by approval in EU in late 13/ early 14. Though Gilead’s Sofosbuvir/IFN/RBV is not far behind, the real competition is for IFN free combinations and MVIR should gain further as the outcome of multiple options in pipeline still remains........ For more detail, please read our report released on October 1, 2013, titled, 'Simeprevir- Good with and without IFN Combinations!'
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1, 2, STELARA, GSK-1605786, Vercirnon, Traficet-EN, Japanese Pharma, Takeda, 4502
Approval of Simeprevir/IFN/RBV combination (TMC435, once daily Protease Inhibitor, PI, R, HCV, partnered with Tibotec/JNJ) in Japan and progress in IFN free combinations with various drugs has helped Medivir’s (MVIR) stock to reach 52 weeks high after a long wait. With a priority status in US, approval of Simeprevir/IFN/RBV in GT1 pts should happen on or before Nov. 28th 2013 followed by approval in EU in late 13/ early 14. Though Gilead’s Sofosbuvir/IFN/RBV is not far behind, the real competition is for IFN free combinations and MVIR should gain further as the outcome of multiple options in pipeline still remains........ For more detail, please read our report released on October 1, 2013, titled, 'Simeprevir- Good with and without IFN Combinations!'
More Publications
Micro Combined Heat and Power Market by Technology (IC Engine, PEMFC, Rankine Cycle Engine, Stirling Engine, SOFC), Type (Engine, Fuel Cell), Application (Residential, Commercial), Capacity (<5kW, 5–10kW, 10–50kW) and Region - Global Forecast to 2029
US$ 2,970.00
May 2024
207 pages
Medivir AB – Initiating as an Outperform - Next in HCV- A Once Daily Protease Inhibitor Option
US$ 140.00
June 2011
6 pages
Polymerase + Protease Inhibitor: Two Good Can Become the Best
US$ 90.00
July 2011
4 pages
MEDIVIR AB - Many Cooks - Likely to Steal the Show
US$ 140.00
November 2011
3 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
August 2011
6 pages
